These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 18977255

  • 21. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG, Pittner R, Jodka C, Smith P, Young A.
    Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
    [Abstract] [Full Text] [Related]

  • 22. Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates neointimal hyperplasia after vascular injury.
    Hirata Y, Kurobe H, Nishio C, Tanaka K, Fukuda D, Uematsu E, Nishimoto S, Soeki T, Harada N, Sakaue H, Kitagawa T, Shimabukuro M, Nakaya Y, Sata M.
    Eur J Pharmacol; 2013 Jan 15; 699(1-3):106-11. PubMed ID: 23220706
    [Abstract] [Full Text] [Related]

  • 23. Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice.
    Kim TH, Park CW, Kim HY, Chi MH, Lee SK, Song YM, Jiang HH, Lim SM, Youn YS, Lee KC.
    Biol Pharm Bull; 2012 Jan 15; 35(7):1076-83. PubMed ID: 22791155
    [Abstract] [Full Text] [Related]

  • 24. A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys.
    Zhang L, Wang L, Meng Z, Gan H, Gu R, Wu Z, Gao L, Zhu X, Sun W, Li J, Zheng Y, Dou G.
    Biochem Biophys Res Commun; 2014 Mar 07; 445(2):511-6. PubMed ID: 24565847
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
    Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA.
    Int J Pharm; 2008 May 22; 356(1-2):231-8. PubMed ID: 18291606
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.
    J Pharmacol Exp Ther; 2006 Aug 22; 318(2):914-21. PubMed ID: 16648370
    [Abstract] [Full Text] [Related]

  • 29. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
    Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, Fujitani Y, Watada H.
    Biochem Biophys Res Commun; 2009 Dec 18; 390(3):809-14. PubMed ID: 19836346
    [Abstract] [Full Text] [Related]

  • 30. Partial blockade of Kv2.1 channel potentiates GLP-1's insulinotropic effects in islets and reduces its dose required for improving glucose tolerance in type 2 diabetic male mice.
    Sukma Rita R, Dezaki K, Kurashina T, Kakei M, Yada T.
    Endocrinology; 2015 Jan 18; 156(1):114-23. PubMed ID: 25337656
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, augments the effects of orally delivered exenatide and pramlintide acetate on energy balance and glycemic control in insulin-resistant male C57BLK/6-m db/db mice.
    Leinung MC, Grasso P.
    Regul Pept; 2012 Nov 10; 179(1-3):33-8. PubMed ID: 22960403
    [Abstract] [Full Text] [Related]

  • 34. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart.
    Sonne DP, Engstrøm T, Treiman M.
    Regul Pept; 2008 Feb 07; 146(1-3):243-9. PubMed ID: 17976835
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice.
    Lee J, Lee C, Kim TH, Chi SC, Moon HR, Oh KT, Lee ES, Lee KC, Youn YS.
    Regul Pept; 2012 Aug 20; 177(1-3):68-72. PubMed ID: 22561689
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA.
    Diabetologia; 2002 Oct 20; 45(10):1410-5. PubMed ID: 12378382
    [Abstract] [Full Text] [Related]

  • 39. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.
    Ozyazgan S, Kutluata N, Afşar S, Ozdaş SB, Akkan AG.
    Pharmacology; 2005 Jun 20; 74(3):119-26. PubMed ID: 15746570
    [Abstract] [Full Text] [Related]

  • 40. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues.
    Tews D, Werner U, Eckel J.
    Horm Metab Res; 2008 Mar 20; 40(3):172-80. PubMed ID: 18348079
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.